Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EPRX Eupraxia Pharmaceuticals	$3.93 +1.8%	$3.74	$2.20 ▼ $4.48	$141.31M	0.65	13,165 shs	700 shs
KRRO Korro Bio	$13.53 -0.1%	$14.65	$10.29 ▼ $98.00	$127.06M	2.45	110,700 shs	20,203 shs
NKTX Nkarta	$1.86 -0.3%	$1.85	$1.31 ▼ $8.23	$131.63M	0.72	1.06 million shs	150,932 shs
VNRX VolitionRx	$0.69 +7.7%	$0.50	$0.40 ▼ $0.90	$70.37M	1.07	193,921 shs	222,963 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EPRX Eupraxia Pharmaceuticals	0.00%	-1.91%	+0.52%	-5.37%	+42.18%
KRRO Korro Bio	0.00%	-7.20%	-10.39%	-45.97%	-67.45%
NKTX Nkarta	0.00%	-2.11%	+6.90%	+14.81%	-69.05%
VNRX VolitionRx	0.00%	+14.77%	+47.89%	+11.52%	-10.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EPRX Eupraxia Pharmaceuticals	2.4858 of 5 stars	3.7	1.0	3.3	0.0	0.6
KRRO Korro Bio	3.5375 of 5 stars	4.6	3.0	4.1	0.0	0.6
NKTX Nkarta	3.6134 of 5 stars	4.6	3.0	3.0	1.7	0.6
VNRX VolitionRx	1.9795 of 5 stars	3.5	0.0	2.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EPRX Eupraxia Pharmaceuticals	3.33	Buy	$10.50	167.18% Upside
KRRO Korro Bio	3.29	Buy	$102.43	657.05% Upside
NKTX Nkarta	3.13	Buy	$14.33	672.69% Upside
VNRX VolitionRx	3.00	Buy	$3.50	410.95% Upside

Current Analyst Ratings Breakdown

Latest VNRX, NKTX, EPRX, and KRRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	EPRX Eupraxia Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Speculative Buy
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
6/10/2025	VNRX VolitionRx	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00
5/15/2025	NKTX Nkarta	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/15/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
5/13/2025	KRRO Korro Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
5/13/2025	KRRO Korro Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$155.00 ➝ $90.00
5/8/2025	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$115.00 ➝ $100.00
4/30/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/29/2025	KRRO Korro Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	KRRO Korro Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	$0.03 per share	N/A
KRRO Korro Bio	$4.82M	26.36	N/A	N/A	$21.19 per share	0.64
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.56 per share	N/A
VNRX VolitionRx	$1.31M	53.94	N/A	N/A	($0.11) per share	-6.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EPRX Eupraxia Pharmaceuticals	-$28.22M	-$0.76	N/A	N/A	N/A	N/A	-219.64%	-96.00%	8/6/2025 (Estimated)
KRRO Korro Bio	-$81.17M	-$9.44	N/A	N/A	N/A	N/A	-50.25%	-38.48%	8/12/2025 (Estimated)
NKTX Nkarta	-$117.50M	-$1.51	N/A	N/A	N/A	N/A	-27.13%	-21.67%	8/12/2025 (Estimated)
VNRX VolitionRx	-$35.32M	-$0.27	N/A	∞	N/A	-2,321.14%	N/A	-163.39%	N/A

Latest VNRX, NKTX, EPRX, and KRRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	NKTX Nkarta	-$0.44	-$0.43	+$0.01	-$0.43	N/A	N/A
5/7/2025	Q1 2025	KRRO Korro Bio	-$2.60	-$2.49	+$0.11	-$2.49	$0.13 million	$2.55 million
5/6/2025	Q1 2025	EPRX Eupraxia Pharmaceuticals	-$0.19	-$0.21	-$0.02	-$0.21	N/A	N/A
3/26/2025	Q4 2024	NKTX Nkarta	-$0.41	-$0.35	+$0.06	-$0.35	N/A	N/A
3/20/2025	Q4 2024	EPRX Eupraxia Pharmaceuticals	-$0.20	-$0.21	-$0.01	-$0.21	N/A	N/A
3/18/2025	Q4 2024	KRRO Korro Bio	-$2.33	-$2.26	+$0.07	-$2.26	N/A	$2.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EPRX Eupraxia Pharmaceuticals	N/A	4.17	4.17
KRRO Korro Bio	N/A	11.23	11.23
NKTX Nkarta	N/A	12.91	12.91
VNRX VolitionRx	N/A	0.22	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EPRX Eupraxia Pharmaceuticals	N/A
KRRO Korro Bio	13.18%
NKTX Nkarta	80.54%
VNRX VolitionRx	8.09%

Insider Ownership

Company	Insider Ownership
EPRX Eupraxia Pharmaceuticals	N/A
KRRO Korro Bio	4.60%
NKTX Nkarta	8.40%
VNRX VolitionRx	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EPRX Eupraxia Pharmaceuticals	29	35.96 million	N/A	N/A
KRRO Korro Bio	70	9.39 million	8.86 million	No Data
NKTX Nkarta	140	70.96 million	64.43 million	Optionable
VNRX VolitionRx	80	103.02 million	80.80 million	Optionable

VNRX, NKTX, EPRX, and KRRO Headlines

Recent News About These Companies

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

June 12, 2025 | prnewswire.com

Jones Trading Initiates Coverage of VolitionRx (VNRX) with Buy Recommendation

June 12, 2025 | msn.com

Jones Trading Begins Coverage on VolitionRx (NYSE:VNRX)

June 11, 2025 | americanbankingnews.com

VolitionRx (NYSE:VNRX) Coverage Initiated at Jones Trading

June 10, 2025 | marketbeat.com

VolitionRx director Guy Innes buys $10,772 in common stock

June 5, 2025 | investing.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 20,000 Shares of Stock

June 5, 2025 | insidertrades.com

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

June 4, 2025 | prnewswire.com

VolitionRx Limited (NYSE:VNRX) Director Buys $10,800.00 in Stock

June 4, 2025 | marketbeat.com

VolitionRX shares hold as Benchmark maintains rating

May 21, 2025 | uk.investing.com

VolitionRx Limited (AMEX:VNRX) Q1 2025 Earnings Call Transcript

May 20, 2025 | msn.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Insider Acquires 50,000 Shares of Stock

May 20, 2025 | insidertrades.com

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

May 19, 2025 | prnewswire.com

VolitionRX aims for cash flow neutrality in 2025 as human diagnostics licensing advances

May 16, 2025 | msn.com

VolitionRX Limited (VNRX) Q1 2025 Earnings Call Transcript

May 16, 2025 | seekingalpha.com

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

May 15, 2025 | prnewswire.com

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

May 12, 2025 | prnewswire.com

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption

May 7, 2025 | prnewswire.com

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

April 29, 2025 | prnewswire.com

VolitionRx enters new sales agreement, terminates old one

April 24, 2025 | investing.com

VolitionRx initiated with a Buy at H.C. Wainwright

April 8, 2025 | markets.businessinsider.com

HC Wainwright & Co. Initiates Coverage of VolitionRx (VNRX) with Buy Recommendation

April 8, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNRX, NKTX, EPRX, and KRRO Company Descriptions

Eupraxia Pharmaceuticals NASDAQ:EPRX

$3.93 +0.07 (+1.81%)

As of 12:05 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Korro Bio NASDAQ:KRRO

$13.53 -0.01 (-0.07%)

As of 12:45 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Nkarta NASDAQ:NKTX

$1.86 -0.01 (-0.27%)

As of 12:45 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

VolitionRx NYSE:VNRX

$0.68 +0.05 (+7.74%)

As of 12:45 PM Eastern

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time